Results 151 to 160 of about 1,402,138 (245)

A systematic review of medication adherence and mortality in chronic disease: Implications for clinical guidelines and policy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Objectives This systematic review aims to investigate whether good medication adherence in adults with chronic conditions is associated with a lower mortality risk compared to poor adherence within published literature, and the extent to which this relationship is represented within South African policy and legislation.
Jessica Hamuy Blanco   +4 more
wiley   +1 more source

Acquired thrombotic thrombocytopenic purpura and HIV infection: a case report and review of the literature. [PDF]

open access: yesAnn Hematol
Rao S   +6 more
europepmc   +1 more source

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

open access: yesNature, 2019
Ravindra K. Gupta   +23 more
semanticscholar   +1 more source

Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Levofloxacin is a widely used antibiotic included in rifampicin‐resistant tuberculosis (RR‐TB) treatment. Data describing levofloxacin concentrations in breastmilk and infant exposure are limited. We analysed data from two South African studies of breastfeeding women receiving levofloxacin (750–1000 mg daily) for RR‐TB.
Sharon Sawe   +9 more
wiley   +1 more source

The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.

open access: yesPLoS Medicine, 2005
Global HIV/AIDS Vaccine Enterprise
doaj   +1 more source

Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Mitotane is an adrenolytic drug with cytotoxic effects, registered for the treatment of advanced adrenocortical carcinoma (ACC), a rare but aggressive tumour type with a poor prognosis despite treatment. Recently, the oral multi‐kinase inhibitor cabozantinib has shown promising results as a potential second‐line treatment option.
Annemieke M. Peters van Ton   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy